Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Lymphoma

Free Subscription Articles published in Eur J Haematol Retrieve available abstracts of 68 articles: HTML format

Single Articles

March 2026
1. JELICIC J, Juul-Jensen K, Bukumiric Z, Rask Kragh Jorgensen R, et al
   Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.
   Eur J Haematol. 2026;116:290-301.
   PubMed     Abstract available
   
   
   
2. RAJABIAN N, Axler O, Wisten E, Porwit A, et al
   Restricted Expression of the Constant Region 1 of T-Cell Receptor beta by Flow Cytometry Facilitates Detection of T-Cell Neoplasms With High Specificity but Moderate Predictive Value.
   Eur J Haematol. 2026;116:245-255.
   PubMed     Abstract available
   
   
   
3. DUMINUCO A, Del Fabro V, Santuccio G, Chiarenza A, et al
   Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study.
   Eur J Haematol. 2026;116:235-244.
   PubMed     Abstract available
   
   
   February 2026
4. TIDSWELL R, Owen C, Shafey M, Perry S, et al
   Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
   Eur J Haematol. 2026 Feb 16. doi: 10.1111/ejh.70137.
   PubMed     Abstract available
   
   
   
5. KHATIB H, Parizat A, Halloun J, Shouval R, et al
   Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.
   Eur J Haematol. 2026 Feb 12. doi: 10.1111/ejh.70139.
   PubMed     Abstract available
   
   
   
6. KEDMI M, Ribakovsky E, Porges T, Benjamini O, et al
   Nivolumab Maintenance for Aggressive B-Cell Lymphoma in Remission After First Line Therapy: A Phase 2 Clinical Trial.
   Eur J Haematol. 2026 Feb 11. doi: 10.1111/ejh.70132.
   PubMed    
   
   
   
7. ROBINSON R, Berger T, Shochat T, Aumann S, et al
   Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity.
   Eur J Haematol. 2026 Feb 9. doi: 10.1111/ejh.70136.
   PubMed     Abstract available
   
   
   
8. THIEBLEMONT C, Colrat F, Sellami R, Sivignon M, et al
   Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma.
   Eur J Haematol. 2026 Feb 6. doi: 10.1111/ejh.70131.
   PubMed     Abstract available
   
   
   
9. SKAFI M, Caserta S, Vigna E, Bruzzese A, et al
   Frontline Therapy in Diffuse Large B-Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions.
   Eur J Haematol. 2026 Feb 3. doi: 10.1111/ejh.70129.
   PubMed     Abstract available
   
   
   
10. BERNARDELLI A, Carazzai E, Bugnotto B, Bellinato F, et al
    Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.
    Eur J Haematol. 2026;116:116-128.
    PubMed     Abstract available
    
    
    January 2026
11. HERNANI R, Albert E, Hernani-Morales C, Zuniga S, et al
    Microbiome-Based Modeling of CAR-T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing.
    Eur J Haematol. 2026 Jan 25. doi: 10.1111/ejh.70121.
    PubMed     Abstract available
    
    
    
12. MOGENSEN BH, Nielsen TH, Pedersen MO, Gjerdrum LMR, et al
    Core Needle Biopsies in Patients With Lymphoproliferative Malignancies: An Observational Single-Center Cohort Study.
    Eur J Haematol. 2026;116:85-92.
    PubMed     Abstract available
    
    
    December 2025
13. MARTINO EA, Caserta S, Skafi M, Alvaro ME, et al
    Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based Approaches.
    Eur J Haematol. 2025 Dec 26. doi: 10.1111/ejh.70105.
    PubMed     Abstract available
    
    
    
14. CASERTA S, Martino EA, Skafi M, Alvaro ME, et al
    Beyond PD-1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next-Generation Immune Strategies.
    Eur J Haematol. 2025 Dec 25. doi: 10.1111/ejh.70101.
    PubMed     Abstract available
    
    
    
15. ALSOUQI A, Huang Y, Christian B, Reneau J, et al
    A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.
    Eur J Haematol. 2025 Dec 9. doi: 10.1111/ejh.70064.
    PubMed    
    
    
    
16. MUNKSGAARD L, Pedersen LM, Munksgaard ASE, Gjerdrum LMR, et al
    Time to Next Treatment Within 24 Months (TTNT24) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia: A Population-Based Observational Study.
    Eur J Haematol. 2025 Dec 4. doi: 10.1111/ejh.70073.
    PubMed     Abstract available
    
    
    November 2025
17. CASERTA S, Martino EA, Vigna E, Bruzzese A, et al
    T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.
    Eur J Haematol. 2025 Nov 9. doi: 10.1111/ejh.70063.
    PubMed     Abstract available
    
    
    
18. PICARDI M, Vincenzi A, Giordano C, Pugliese N, et al
    Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers.
    Eur J Haematol. 2025 Nov 6. doi: 10.1111/ejh.70060.
    PubMed     Abstract available
    
    
    September 2025
19. CASERTA S, Martino EA, Vigna E, Bruzzese A, et al
    Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
    Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70036.
    PubMed     Abstract available
    
    
    July 2025
20. FUGLKJAER AD, Kilic DK, Eskesen MH, Simonsen MR, et al
    Machine Learning for Prediction of High-Risk Hospitalizations in Lymphoma Patients: A Danish Population-Based Study.
    Eur J Haematol. 2025 Jul 29. doi: 10.1111/ejh.70012.
    PubMed     Abstract available
    
    
    
21. VAN DER GALIEN HT, Kooistra HAM, Kibbelaar R, Veeger NJGM, et al
    Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.
    Eur J Haematol. 2025 Jul 9. doi: 10.1111/ejh.70003.
    PubMed     Abstract available
    
    
    June 2025
22. ZHU M, Li T, Han S, Zhao D, et al
    Construction of Lymphoma Organoids and Applications in Tumor Microenvironment Research.
    Eur J Haematol. 2025 Jun 30. doi: 10.1111/ejh.14448.
    PubMed     Abstract available
    
    
    
23. ROBIN A, Owen C, Perry S, Street L, et al
    Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Eur J Haematol. 2025 Jun 1. doi: 10.1111/ejh.14443.
    PubMed     Abstract available
    
    
    May 2025
24. YAGI Y, Kanemasa Y, Sasaki Y, Matsubayashi M, et al
    Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.
    Eur J Haematol. 2025 May 26. doi: 10.1111/ejh.14440.
    PubMed     Abstract available
    
    
    
25. RU Y, Tong X, Lin J, Chen F, et al
    Learning-Based Classification of B- and T-Cell Lymphoma on Histopathological Images: A Multicenter Study.
    Eur J Haematol. 2025 May 13. doi: 10.1111/ejh.14433.
    PubMed     Abstract available
    
    
    
26. VON TRESCKOW B, Abrisqueta P, Zamanillo I, Pareja AS, et al
    Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review.
    Eur J Haematol. 2025 May 9. doi: 10.1111/ejh.14423.
    PubMed     Abstract available
    
    
    March 2025
27. LOHRBERG M, Heber M, Ries L, Markus K, et al
    Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
    Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
    PubMed     Abstract available
    
    
    
28. MARZOLINI MAV, Kayani I, Carpenter B, Laurence A, et al
    The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas.
    Eur J Haematol. 2025;114:545-555.
    PubMed     Abstract available
    
    
    February 2025
29. CARIDA G, Martino EA, Bruzzese A, Caracciolo D, et al
    Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.
    Eur J Haematol. 2025 Feb 19. doi: 10.1111/ejh.14401.
    PubMed     Abstract available
    
    
    
30. TAN XXS, Maltez MT, Mallick R, Hamelin L, et al
    Distance to CAR-T Treatment Center Does Not Impede Delivery.
    Eur J Haematol. 2025;114:276-284.
    PubMed     Abstract available
    
    
    January 2025
31. BENNEDSEN TL, Simonsen MR, Jensen P, Brown P, et al
    Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real-World Setting.
    Eur J Haematol. 2025 Jan 9. doi: 10.1111/ejh.14373.
    PubMed     Abstract available
    
    
    
32. STRUSSMANN T, Hermes P, Ihorst G, Finke J, et al
    Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients.
    Eur J Haematol. 2025;114:139-146.
    PubMed     Abstract available
    
    
    December 2024
33. PUCKRIN R, Owen C, Peters A
    Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2024 Dec 27. doi: 10.1111/ejh.14376.
    PubMed     Abstract available
    
    
    
34. BREINHOLT MF, Schejbel L, Gang AO, Christensen IJ, et al
    TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma.
    Eur J Haematol. 2024 Dec 18. doi: 10.1111/ejh.14364.
    PubMed     Abstract available
    
    
    
35. METZNER B, Muller TH, Casper J, Kimmich C, et al
    Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
    Eur J Haematol. 2024 Dec 10. doi: 10.1111/ejh.14355.
    PubMed     Abstract available
    
    
    
36. SIMONSEN MR, Jensen JF, Larsen TS, Gade IL, et al
    The Prevalence of Diffuse Large B-Cell Lymphoma Varies Substantially by Methods Applied: Results From a Population-Based Study.
    Eur J Haematol. 2024 Dec 5. doi: 10.1111/ejh.14359.
    PubMed     Abstract available
    
    
    November 2024
37. VIMALATHAS G, Lang CS, Green TM, Moller MB, et al
    Multilevel Analysis of MYC and BCL2 Aberrations in Diffuse Large B-Cell Lymphoma: Identifying a High-Risk Patient Subgroup Across Cell-of-Origin Using Targeted Sequencing.
    Eur J Haematol. 2024 Nov 20. doi: 10.1111/ejh.14345.
    PubMed     Abstract available
    
    
    
38. GODTFREDSEN SJ, Yonis H, Baech J, Al-Hussainy NR, et al
    Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study.
    Eur J Haematol. 2024 Nov 6. doi: 10.1111/ejh.14334.
    PubMed     Abstract available
    
    
    October 2024
39. MORABITO F, Martino EA, Nizzoli ME, Talami A, et al
    Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.
    Eur J Haematol. 2024 Oct 27. doi: 10.1111/ejh.14335.
    PubMed     Abstract available
    
    
    
40. LIEVIN R, Burroni B, Balducci E, Palmic P, et al
    Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement.
    Eur J Haematol. 2024 Oct 12. doi: 10.1111/ejh.14325.
    PubMed     Abstract available
    
    
    
41. ANDERSEN MD, Wolter K, Enemark MBH, Pedersen MA, et al
    Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.
    Eur J Haematol. 2024 Oct 11. doi: 10.1111/ejh.14326.
    PubMed     Abstract available
    
    
    September 2024
42. MAZZONI C, Argnani L, Casadei B, Broccoli A, et al
    Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.
    Eur J Haematol. 2024 Sep 18. doi: 10.1111/ejh.14306.
    PubMed     Abstract available
    
    
    
43. JELICIC J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, et al
    A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.
    Eur J Haematol. 2024 Sep 10. doi: 10.1111/ejh.14301.
    PubMed     Abstract available
    
    
    July 2024
44. DILBAZ ZG, Denker S, Ankermann C, Bittenbring JT, et al
    Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort study.
    Eur J Haematol. 2024 Jul 31. doi: 10.1111/ejh.14268.
    PubMed     Abstract available
    
    
    
45. RASK KRAGH JORGENSEN R, Jakobsen LH, Eloranta S, Smedby KE, et al
    Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study.
    Eur J Haematol. 2024 Jul 22. doi: 10.1111/ejh.14275.
    PubMed     Abstract available
    
    
    June 2024
46. WASIFUDDIN M, Ilerhunmwuwa NP, Becerra H, Hakobyan N, et al
    Racial disparities in the incidence and survival outcomes in diffuse large B-cell lymphoma in adolescents and young adults.
    Eur J Haematol. 2024 Jun 18. doi: 10.1111/ejh.14255.
    PubMed     Abstract available
    
    
    
47. KURTE MS, Siefen AC, Jakobs F, Poos T, et al
    Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
    Eur J Haematol. 2024 Jun 10. doi: 10.1111/ejh.14248.
    PubMed     Abstract available
    
    
    
48. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
    Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
    Eur J Haematol. 2024;112:984-987.
    PubMed     Abstract available
    
    
    May 2024
49. VELA-OJEDA J, Olivas-Bejarano AC, Montiel-Cervantes LA, Rosales-Cruz E, et al
    Soluble MIC-A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma.
    Eur J Haematol. 2024 May 14. doi: 10.1111/ejh.14230.
    PubMed     Abstract available
    
    
    April 2024
50. PERNAS B, Iacoboni G, Los-Arcos I, Carpio C, et al
    Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.
    Eur J Haematol. 2024 Apr 26. doi: 10.1111/ejh.14207.
    PubMed     Abstract available
    
    
    
51. HARMANEN M, Sorigue M, Khan M, Prusila R, et al
    Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.
    Eur J Haematol. 2024 Apr 25. doi: 10.1111/ejh.14219.
    PubMed     Abstract available
    
    
    
52. RICHARDSON T, Scheid C, Herling M, Frenzel LP, et al
    Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
    Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210.
    PubMed     Abstract available
    
    
    March 2024
53. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    PubMed     Abstract available
    
    
    February 2024
54. HEGER JM, d'Hargues Y, Kleinert F, Mattlener J, et al
    Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Eur J Haematol. 2024 Feb 18. doi: 10.1111/ejh.14191.
    PubMed     Abstract available
    
    
    
55. MASSOUD R, Naim H, Klyuchnikov E, Janson D, et al
    Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
    Eur J Haematol. 2024;112:276-285.
    PubMed     Abstract available
    
    
    
56. HO M, Zanwar S, Paludo J
    Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Eur J Haematol. 2024;112:197-210.
    PubMed     Abstract available
    
    
    January 2024
57. YAMAUCHI N, Maruyama D
    Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14166.
    PubMed     Abstract available
    
    
    
58. ZEREMSKI V, Adolph L, Beer S, Berisha M, et al
    Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
    Eur J Haematol. 2024 Jan 2. doi: 10.1111/ejh.14159.
    PubMed     Abstract available
    
    
    
59. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    PubMed     Abstract available
    
    
    December 2023
60. LOPEZ M, Kainthla R, Lazarte S, Chen W, et al
    Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14163.
    PubMed     Abstract available
    
    
    
61. RAMDANY H, Lofaro T, Deplano S
    The Haemato-Oncology Frailty (HOF) score to assess frailty in lymphoma.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14152.
    PubMed     Abstract available
    
    
    
62. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    PubMed     Abstract available
    
    
    October 2023
63. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    PubMed     Abstract available
    
    
    September 2023
64. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    PubMed     Abstract available
    
    
    
65. ZHU H, Zhuang Z, Wang W, Zhao D, et al
    Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
    Eur J Haematol. 2023 Sep 18. doi: 10.1111/ejh.14078.
    PubMed     Abstract available
    
    
    
66. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    PubMed     Abstract available
    
    
    
67. CAI F, Zhang J, Gao H, Shen H, et al
    Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14103.
    PubMed     Abstract available
    
    
    July 2023
68. MATTSSON A, Sylvan SE, Axelsson P, Ellin F, et al
    Idelalisib (PI3Kdelta inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
    Eur J Haematol. 2023 Jul 27. doi: 10.1111/ejh.14065.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum